Home Cart Sign in  
Chemical Structure| 1308672-74-3 Chemical Structure| 1308672-74-3

Structure of Sulfatinib
CAS No.: 1308672-74-3

Chemical Structure| 1308672-74-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sulfatinib is an inhbitor of KDR and FGFR1 with IC50 values of 0.021 μM and 0.053 μM respectively. It also shows inhibition of hERG (IC50 = 6.8 μM).

Synonyms: Surufatinib; HMPL-012; Surfatinib

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sulfatinib

CAS No. :1308672-74-3
Formula : C24H28N6O3S
M.W : 480.58
SMILES Code : O=S(CC1=CC=CC(NC2=NC=CC(OC3=CC4=C(NC(C)=C4)C=C3)=N2)=C1)(NCCN(C)C)=O
Synonyms :
Surufatinib; HMPL-012; Surfatinib
InChI Key :TTZSNFLLYPYKIL-UHFFFAOYSA-N
Pubchem ID :52920501

Safety of Sulfatinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Sulfatinib

RTK

Isoform Comparison

Biological Activity

Target
  • FGFR1

    FGFR1, IC50:15 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05973968 Neuroendocrine Tumor Grade 3 NOT_YET_RECRUITING 2025-06-25 -
NCT05171439 Hepatocellular Carcinoma PHASE2 UNKNOWN 2023-03-01 Nanjing Drum tower hospital, N... More >>anjing, Jiangsu, 210009, China Less <<
NCT05106777 Sarcoma PHASE2 RECRUITING 2023-12-10 Sun Yat-Sen Univerisity, Guang... More >>zhou, Guangdong, China Less <<
NCT04764006 Advanced Colorectal Cancer PHASE2 UNKNOWN 2023-11-01 China, Fujian, Fuzhou, Fujian,... More >> 350014, China Less <<
NCT06110650 Soft Tissue Sarcoma Adult NOT_YET_RECRUITING 2025-08-15 -
NCT04910854 Head and Neck Cancers - Saliva... More >>ry Gland Less << PHASE2 UNKNOWN 2023-12-31 Fudan University Shanghai Canc... More >>er Center, Shanghai, Shanghai, 200032, China Less <<
NCT02133157 Tumor PHASE1 COMPLETED 2025-10-14 Academy of Military Medical Af... More >>filiated Hopital, Beijing, 100071, China Less <<
NCT02267967 Neuroendocrine Tumors PHASE1 COMPLETED 2017-08-23 Peking Union Medical College H... More >>ospital, Beijing, Beijing, 100032, China|the 307 Hospital of People's Liberation Army, Beijing, Beijing, 100071, China|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, 200433, China|West China Hospital, Sichuan University, Chengdu, Sichuan, 610047, China|The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, 310006, China Less <<
NCT02320409 Healthy PHASE1 COMPLETED 2025-04-15 Shanghai Xuhui Central Hospita... More >>l, Shanghai, Shanghai, 200031, China Less <<
NCT05077384 Neuroendocrine Tumors|Non-hema... More >>tologic Malignancy Less << PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2025-12-24 Kyushu University Hospital, Fu... More >>kuoka, 812-0054, Japan|Fukuoka Sanno Hospital, Fukuoka, 814-0001, Japan|Kagawa University Hospital, Kagawa, 761-0793, Japan|National Cancer Centre Hospital East, Kashiwa-shi, 277-8577, Japan|Kyoto University Hospital, Kyoto, 606-8507, Japan|Kyorin University Hospital, Mitaka, 181-8611, Japan|Aichi Cancer Centre, Nagoya, 464-8681, Japan|Kansia Electric Power Hospital, Osaka, 553-0003, Japan|Hokkaido University Hospital, Sapporo, 060-8648, Japan|Tohoku University Hospital, Sendai, 890-8574,, Japan|National Cancer Centre Hospital, Tokyo, 104-004, Japan|Yokohama City University Hospital, Yokohama, 236-0004, Japan Less <<
NCT02966821 Biliary Tract Cancer PHASE2 COMPLETED 2018-11-30 Peking Union Medical College H... More >>ospital, Beijing, Beijing, 100032, China|The 307th Hospital of Military Chinese People's Liberation Army, Beijing, Beijing, 100071, China|Heilongjiang Cancer Hospital, Ha'erbin, Heilongjiang, 150040, China|Shanghai Zhongshan Hospital, Shanghai, Shanghai, 200032, China|Tianjin medical university cancer institute&hospital, Tianjin, Tianjin, 300060, China Less <<
NCT05282433 Hepatocellular Carcinoma; Targ... More >>eted Therapy; Progression-free Survival Less << PHASE2 UNKNOWN 2024-12-31 Zhongnan Hopital of Wuhan Univ... More >>ersity, Wuhan, Hubei, 430070, China Less <<
NCT04814732 Neuroendocrine Tumors NO_LONGER_AVAILABLE - Rocky Mountain Cancer Center, ... More >>Denver, Colorado, 80218, United States|Mercy Medical Center, Medical Oncology & Hematology, Baltimore, Maryland, 21202, United States|Karmanos Cancer Center, Detroit, Michigan, 48201, United States|MidAmerica Cancer Care, Kansas City, Missouri, 64114, United States|Summit Medical Group, Florham Park, New Jersey, 07932, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Providence Cancer Institute Franz Clinic, Providence Health & Services, Portland, Oregon, 97213, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|Intermountain Healthcare, Murray, Utah, 84107, United States|Intermountain Cancer Center, Saint George, Utah, 84790, United States Less <<
NCT05064852 Biliary Tract Carcinoma UNKNOWN 2023-12-20 -
NCT04579679 Neuroendocrine Tumours|Neuroen... More >>docrine Tumour of the Lung|Small Intestinal NET Less << PHASE2 ACTIVE_NOT_RECRUITING 2024-09-15 University of Alabama, Birming... More >>ham (UAB), Birmingham, Alabama, 35233, United States|University of California Irvine Medical Center UCIMC - H.H. Chao Comprehensive Digestive Disease Center CDDC, Orange, California, 92868, United States|Emory University, Winship Cancer Institute, Atlanta, Georgia, 30322-1013, United States|Stony Brook Cancer Center, Stony Brook, New York, 11794, United States|Houston Methodist, Houston, Texas, 77030, United States|CHU Bordeaux, Pessac, 33604, France|Institut Gustave Roussy, Villejuif, 94800, France|Charite Universitatsmedizin Berlin, Berlin, 13353, Germany|Universitaetsklinikum Erlangen, Erlangen, 91054, Germany|Universitatsklinikum Essen, Klinik fur Endokrinologie, Essen, 45147, Germany|Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari, Bari, 70124, Italy|ASST-Spedali Civili di Brescia, Brescia, 25123, Italy|Universita degli Studi di Firenze - Azienda Ospedaliero Universitaria Careggi (AOUC), Firenze, 50134, Italy|Istituto Europeo di Oncologia, Milano, 20141, Italy|Haukeland University Hospital, Bergen, 5021, Norway|Oslo University Hospital Rikshospitalet, Oslo, 0372, Norway|Institut Catala d'Oncologis (ICO) - Hospital Duran i Reynals, Barcelona, 8013, Spain|Hospital Vall Hebron, Barcelona, 8035, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Sarah Cannon Research Institute, London, W1G 6AD, United Kingdom|Christie Hospital, Manchester, M20 4BX, United Kingdom Less <<
NCT02614495 Thyroid Carcinoma PHASE2 COMPLETED 2018-09-30 Peking Union Medical College H... More >>ospital, Beijing, Beijing, 100032, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China Less <<
NCT05013515 Salivary Gland Carcinomas UNKNOWN 2025-06-24 Shanghai Ninth People's Hospit... More >>al Affiliated to Shanghai Jiao Tong University, Shanghai, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.08mL

0.42mL

0.21mL

10.40mL

2.08mL

1.04mL

20.81mL

4.16mL

2.08mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories